Having trouble accessing articles? Reset your cache.

Ahead of FDA decisions on one antibiotic, Nabriva plans resubmission of another

As it awaits FDA's decisions on twin NDAs for lefamulin, Nabriva said it plans to resubmit an NDA early next quarter for another one of its antibiotics following a complete response

Read the full 316 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE